Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.4K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.4K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Weekly Variability of an Objective Bradykinesia Score in Parkinson's Disease-An Observational Longitudinal Study.

Journal of clinical medicine·2026
Same author

Real-World Safety and Effectiveness of 24-Hour Foslevodopa/Foscarbidopa in Parkinson's Disease: ROSSINI Study 6-Month Interim Results.

Neurology and therapy·2026
Same author

Systematic literature review of secondary primary malignancies related to a CAR-T treatment in patients with multiple myeloma, lymphoma or leukemia.

Cancer treatment and research communications·2026
Same author

Wearable sensor measurements in relation to clinical characteristics and mortality in patients with Parkinson's disease.

Neurological research and practice·2026
Same author

Preliminary Results of Phenotype Characterisation for Cerebellar Ataxia using Automated Lower Limb Assessment.

Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference·2025
Same author

Association between gout, hyperuricaemia and Parkinson's disease risk: a cohort study in western Sweden (2001-2017).

Rheumatology advances in practice·2025

Related Experiment Video

Updated: Apr 13, 2026

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

16.6K

An objective fluctuation score for Parkinson's disease.

Malcolm K Horne1, Sarah McGregor2, Filip Bergquist3

  • 1Florey Institute for Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, Australia; Centre for Clinical Neurosciences and Neurological Research, St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia.

Plos One
|May 1, 2015
PubMed
Summary
This summary is machine-generated.

A new Fluctuation Score, derived from an accelerometry system, objectively measures Parkinson's Disease motor fluctuations. This score aids in identifying disease progression and potential therapeutic adjustments for better patient management.

More Related Videos

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

3.7K
Community-based Adapted Tango Dancing for Individuals with Parkinson's Disease and Older Adults
09:19

Community-based Adapted Tango Dancing for Individuals with Parkinson's Disease and Older Adults

Published on: December 9, 2014

26.5K

Related Experiment Videos

Last Updated: Apr 13, 2026

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

16.6K
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

3.7K
Community-based Adapted Tango Dancing for Individuals with Parkinson's Disease and Older Adults
09:19

Community-based Adapted Tango Dancing for Individuals with Parkinson's Disease and Older Adults

Published on: December 9, 2014

26.5K

Area of Science:

  • Neurology
  • Biomedical Engineering
  • Movement Disorders

Background:

  • Accurate assessment of motor fluctuations is crucial for Parkinson's Disease (PD) management.
  • Current methods for quantifying PD fluctuations lack reliability and objectivity.
  • An objective measure is needed to track disease progression and treatment efficacy.

Purpose of the Study:

  • To evaluate a novel Fluctuation Score derived from an accelerometry-based system.
  • To assess the score's ability to objectively measure motor fluctuations in Parkinson's Disease patients.
  • To determine the score's utility in distinguishing fluctuating from non-fluctuating patients and monitoring therapeutic interventions.

Main Methods:

  • Developed a Fluctuation Score using an algorithm based on the interquartile range of bradykinesia and dyskinesia.
  • Collected data using an accelerometry system every 2 minutes between 0900-1800 for at least 6 days.
  • Calculated the score in newly diagnosed PD patients, those with known disease duration, and control subjects.

Main Results:

  • The Fluctuation Score effectively distinguished between fluctuating and non-fluctuating Parkinson's Disease patients with high sensitivity and selectivity.
  • Scores were significantly lower after deep brain stimulation, indicating adequate motor control.
  • Newly diagnosed patients showed an initial loss of fluctuation, with scores either stabilizing or escalating to indicate more severe fluctuations over time.

Conclusions:

  • The developed Fluctuation Score is a promising tool for identifying progressive motor fluctuations in Parkinson's Disease.
  • This objective score can assist clinicians in making timely therapeutic adjustments.
  • The Fluctuation Score shows potential as a valuable research tool for further PD studies.